Historic Price Surge and Market Outperformance
On 17 July 2026, Parmax Pharma Ltd’s stock price surged to Rs.100.91, setting a new 52-week and all-time high. This price level represents a substantial increase from its 52-week low of Rs.22.60, reflecting a remarkable gain of 346.50% from the lowest point in the past year. The stock opened at this peak price and maintained it throughout the trading session, closing with a day gain of 1.99%, outperforming the Sensex’s 0.98% rise on the same day.
Over the last 21 consecutive trading days, Parmax Pharma has delivered an impressive 51.31% return, underscoring sustained buying interest and momentum. This performance notably outpaces the Pharmaceuticals & Biotechnology sector, with the stock outperforming its sector by 3.21% on the day of the record high.
Long-Term Performance Comparison
Examining Parmax Pharma’s returns over various time frames reveals a striking contrast with broader market benchmarks. The stock has delivered a 3-month return of 236.25%, while the Sensex declined by 0.70% during the same period. Year-to-date, Parmax Pharma has surged 198.29%, compared to the Sensex’s negative 8.54%. Over one year, the stock’s gain stands at 151.90%, whereas the Sensex fell by 5.24%. Even over a three-year horizon, Parmax Pharma’s 237.49% return significantly outstrips the Sensex’s 17.05% gain. However, over five years, the stock’s 64.08% appreciation is more modest but still ahead of the Sensex’s 46.68% rise. The 10-year return for Parmax Pharma is recorded as 0.00%, indicating either a lack of data or listing history for that period.
Technical Indicators Confirm Bullish Momentum
The technical landscape for Parmax Pharma is strongly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling robust upward momentum. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all reflect bullish trends on both weekly and monthly timeframes. The Relative Strength Index (RSI) remains bearish, suggesting some caution on short-term overbought conditions, but this has not deterred the overall positive trend.
The immediate support level remains at the 52-week low of Rs.22.60, while the stock has surpassed major resistance levels at Rs.38.75 (200 DMA), Rs.44.32 (100 DMA), and Rs.82.59 (20 DMA), culminating in the current all-time high of Rs.100.91.
Valuation and Financial Metrics
Despite the strong price performance, Parmax Pharma’s valuation metrics reflect its current financial profile as a loss-making entity. The Price-to-Earnings (P/E) ratio is not applicable due to losses, and the Price-to-Book Value (P/BV) stands at a negative 6.02x. Enterprise Value multiples such as EV/EBITDA and EV/EBIT are also negative, at -13.38x and -10.41x respectively, while EV/Sales is 3.95x and EV/Capital Employed is 10.15x. The PEG ratio is not available.
The company does not currently pay dividends, with dividend yield and payout ratios marked as not applicable.
Quality and Financial Trends
Parmax Pharma is classified as a below-average quality company based on long-term financial performance. Key quality factors include a 5-year sales decline of 14.30% and a significant 5-year EBIT contraction of 225.63%. The company maintains a net cash position, with negative net debt to equity of -1.77, and no promoter share pledging. Average return on capital employed (ROCE) is weak at -28.89%, while average return on equity (ROE) is modest at 5.12%.
Short-term financial trends remain negative as of March 2026, with net sales over the latest six months down by 31.23% to Rs.7.64 crores and profit after tax for nine months declining by 50.12% to a loss of Rs.3.39 crores. The company’s quarterly earnings per share (EPS) reached a highest point of negative Rs.1.55, reflecting ongoing challenges in profitability.
Trading Volumes and Market Activity
Delivery volumes have shown a positive trend, with a 31.5% increase over the past month and a notable 76.16% rise in delivery volume on the day of the all-time high compared to the 5-day average. This indicates heightened investor participation and confidence in the stock’s upward trajectory.
Mojo Score and Market Sentiment
MarketsMOJO assigns Parmax Pharma a Mojo Score of 31.0 with a current Mojo Grade of Sell, upgraded from a previous Strong Sell on 8 June 2026. The stock is included in thematic lists under the Pharmaceuticals & Biotechnology sector, reflecting its micro-cap status and sector affiliation.
Summary of the Stock’s Journey
Parmax Pharma Ltd’s ascent to an all-time high of Rs.100.91 marks a significant milestone in its market history. The stock’s strong performance over recent months, supported by bullish technical indicators and sustained gains, contrasts with its underlying financial challenges. While valuation multiples and quality metrics highlight areas of concern, the stock’s price action demonstrates notable resilience and momentum within the Pharmaceuticals & Biotechnology sector.
This achievement underscores the dynamic nature of micro-cap stocks, where market sentiment and technical factors can drive substantial price movements despite fundamental headwinds.
